2012
DOI: 10.2147/ca.s30127
|View full text |Cite
|
Sign up to set email alerts
|

Telavancin in the treatment of invasive Gram-positive infections

Abstract: Telavancin is a newer once-daily lipoglycopeptide with activity against Gram-positive bacteria, including those that are resistant to conventional antibiotics like beta-lactams. The results of recent clinical trials led to registration of telavancin for use in skin and skin structure infections in the US and Canada and for nosocomial pneumonia in Europe, based primarily on the favorable results of clinical trials. We review the evidence for use of telavancin in Gram-positive intravascular infections, focusing … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 38 publications
(50 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?